BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 24117170)

  • 21. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-small cell lung cancer--genetic predictors.
    Koudelakova V; Kneblova M; Trojanec R; Drabek J; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):125-36. PubMed ID: 23733083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular pathology of lung cancer: key to personalized medicine].
    Cheng L; Li Y; Zhang SB; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical testing for molecular targets for personalized treatment in lung cancer.
    Lam DC
    Respirology; 2013 Feb; 18(2):233-7. PubMed ID: 22957484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
    Passiglia F; Bronte G; Castiglia M; Listì A; Calò V; Toia F; Cicero G; Fanale D; Rizzo S; Bazan V; Russo A
    Expert Opin Biol Ther; 2015; 15(11):1553-66. PubMed ID: 26360115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of biomarkers in men and women.
    Planchard D; Loriot Y; Goubar A; Commo F; Soria JC
    Semin Oncol; 2009 Dec; 36(6):553-65. PubMed ID: 19995647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of multiple primary lung cancer: a systematic review.
    Xue X; Liu Y; Pan L; Wang Y; Wang K; Zhang M; Wang P; Wang J
    J Int Med Res; 2013 Dec; 41(6):1779-87. PubMed ID: 24265329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovative personalized medicine in gastric cancer: time to move forward.
    Lee J; Kim KM; Kang WK; Ou SH
    Clin Genet; 2014 Jul; 86(1):37-43. PubMed ID: 24749947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?
    Aggarwal C; Somaiah N; Simon GR
    J Natl Compr Canc Netw; 2010 Jul; 8(7):822-32. PubMed ID: 20679541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of STAT3 in Resistance of Non-small Cell Lung Cancer].
    Sun S; Jin S; Guo R
    Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):457-463. PubMed ID: 31315785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer.
    Liao ZX; Kempson IM; Hsieh CC; Tseng SJ; Yang PC
    Drug Discov Today; 2021 Nov; 26(11):2508-2514. PubMed ID: 34325010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologic and molecular prognostic factors--impact on treatment of patients with non-small cell lung cancer.
    Johnson BE
    Chest; 1995 Jun; 107(6 Suppl):287S-290S. PubMed ID: 7781407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological prognostic factors in non-small cell lung cancer.
    Scagliotti GV; Masiero P; Pozzi E
    Lung Cancer; 1995 Apr; 12 Suppl 1():S13-25. PubMed ID: 7551921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer.
    Rooney C; Sethi T
    Chest; 2015 Oct; 148(4):1063-1072. PubMed ID: 26182407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STAT3: Versatile Functions in Non-Small Cell Lung Cancer.
    Mohrherr J; Uras IZ; Moll HP; Casanova E
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylation of basic helix-loop-helix transcription factor Twist in development and disease.
    Xue G; Hemmings BA
    Biochem Soc Trans; 2012 Feb; 40(1):90-3. PubMed ID: 22260671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC).
    Gorgisen G; Ozes D; Pehlivanoglu S; Erdogan A; Dertsiz L; Ozbilim G; Ozbudak IH; Savas B; Ozes ON
    Exp Lung Res; 2013 Nov; 39(9):387-98. PubMed ID: 24117170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS mutation: should we test for it, and does it matter?
    Roberts PJ; Stinchcombe TE
    J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.